Prodromal Alpha-Synuclein Screening in Parkinson's Disease Study

The PASS-PD study is set out to screen individuals from the general population with an increased risk for the development of Parkinson's Disease (PD) and to investigate this highly enriched cohort longitudinally for five year. A special focus is placed on implementation of ethical standards for early risk disclosure in PD.

The PASS-PP Study is designed to combine the latest developments in clinical and biomarker research to 1. understand the distribution of risk profiles for PD in the general population, especially regarding non-motor symptoms 2. identify subjects with a likelihood of developing PD 3. follow individuals with a high likelihood/risk to develop PD in the future (compared to individuals with low risk and) in a prospective study 4. understand the potential of biological markers to increase prediction of progression/conversion 5. identify subtypes of PD patients, by providing a detailed clinical phenotyping with a main focus on non-motor symptoms cluster 6. provide a framework of ethical handling of early risk disclosure in PD